We sought to further develop our genetic interference data demonstrating PRMT5 requirement in MNA neuroblastoma [5] by evaluating the highly selective, first-in-class PRMT5 inhibitor GSK3203591 on a panel of neuroblastoma cell lines. The gene discussed is PRMT5; the disease is neuroblastoma.